Cancer News and Research

Latest Cancer News and Research

Study shows NK cells use bungee-like nanotube to destroy dangerous cells

Immune cells ensnare dangerous cells that are on the run with a bungee-like nanotube, according to research published today in the Proceedings of the National Academy of Sciences. The study, by researchers from Imperial College London, shows that natural killer (NK) cells use this bungee to destroy cells that could otherwise escape them.

9 Mar 2010

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

9 Mar 2010

National Asbestos Awareness Week to raise awareness about prevalence of asbestos-related diseases

The Asbestos Disease Awareness Organization, the leading organization serving as the voice of asbestos victims, today applauds Representative Steve Cohen (D-TN - 09) and cosponsors for introducing a resolution that declares the first week of April as “National Asbestos Awareness Week” and seeks to “raise public awareness about the prevalence of asbestos-related diseases and the dangers of asbestos exposure.”

9 Mar 2010

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Exelixis, Inc. today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program.

9 Mar 2010

Elderly women over 70 have higher prevalence of cancer detected in second breast by MRI

Postmenopausal women, including those over 70 years old, who have been newly diagnosed with cancer in one breast have higher cancer detection rates when the other breast is scanned for tumors with MRI, compared to premenopausal women, say researchers at the Mayo Clinic campus in Florida.

9 Mar 2010

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

The Journal of the American Academy of Dermatology (JAAD) has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses - 2.5% and 3.75% - administered daily on a 2-week treatment cycle. The study demonstrates that both formulations were superior to placebo, and that imiquimod 3.75% on a daily 2-week treatment cycle is superior to imiquimod 2.5% in treating actinic keratosis (AK) on a large surface area - the face or balding scalp.

9 Mar 2010

Nanoparticles: Targeted cancer therapy

Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.

9 Mar 2010

Corning Lab for Cure program

Corning Incorporated today announced the Corning Lab for the Cure™ program, a first-of-its-kind corporate sponsorship agreement with Susan G. Komen for the Cure®.

9 Mar 2010

Clinical and scientific advances made in the field of neuro-oncology

Many important clinical and basic scientific advances have been made in the past five years in the field of neuro-oncology, according to an editorial and several articles in the March issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Mar 2010

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

9 Mar 2010

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.

9 Mar 2010

Black and Hispanic Medicare beneficiaries with heart failure less likely to receive hospice care

Black and Hispanic Medicare beneficiaries with heart failure appear less likely to receive hospice care than white patients with the same condition, according to a report in the March 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Mar 2010

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

The Journal of the American Academy of Dermatology has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses – 2.5% and 3.75% – administered daily on either 2-week or 3-week treatment cycles.

9 Mar 2010

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors.

9 Mar 2010

Positive results from international study of Oncotype DX breast cancer RS

Genomic Health, Inc. today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen.

9 Mar 2010

California venture capitalist/ philanthropist gifts $6M to Institute for Systems Biology

The Institute for Systems Biology, an independent, non-profit biomolecular research institute, has received a $6 million gift from a California venture capitalist and philanthropist to support strategic organizational objectives.

9 Mar 2010

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.

9 Mar 2010

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

The Society for Biomolecular Sciences will honor three researchers for their substantial contributions to the field of drug discovery. Each recipient will accept their award and speak at the SBS 16th Annual Conference & Exhibition in Phoenix, Arizona, April 11-15, 2010.

9 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Study shows NK cells use bungee-like nanotube to destroy dangerous cells

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

National Asbestos Awareness Week to raise awareness about prevalence of asbestos-related diseases

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Elderly women over 70 have higher prevalence of cancer detected in second breast by MRI

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

Nanoparticles: Targeted cancer therapy

Corning Lab for Cure program

Clinical and scientific advances made in the field of neuro-oncology

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Black and Hispanic Medicare beneficiaries with heart failure less likely to receive hospice care

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

Well-characterized molecular alterations of sarcomas make them ideal models for developing new therapies

Positive results from international study of Oncotype DX breast cancer RS

California venture capitalist/ philanthropist gifts $6M to Institute for Systems Biology

Fenwal receives FDA marketing clearance for Amicus blood cell separator

Three researchers to be honored with SBS Award for achievement in biomolecular sciences and lead discovery

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in